2013
-
Sysmex Succeeds in World's First Practical Application of Technology Employing a Glycosylation Marker to Test Hepatic Fibrosis;
Technology Allows the Degree of Hepatic Fibrosis, from Hepatitis to Cirrhosis of the Liver, to Be Determined Swiftly -
Sysmex Commences a Service (for Research) Involving Analysis of Genetic Expression in Breast Cancer Tissue
- Working toward Personalized Medicine for the Treatment of Breast Cancer - - XN-2000/XN Reagents in the Hematology Field Receive German Design Award
- (Corrections and Corrections to Numerical Data) Partial Correction to Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014 (PDF：257KB)
- Sysmex Wins Awards in 2013 Local Commendation for Invention of Kinki
-
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014
*Revised on November 18, 2013 (PDF：154KB) -
National Cancer Center and Sysmex Enter into Collaboration Agreement to Develop Cancer Diagnostic Reagents
- Promoting the Development of New Biomarkers - - Joint Establishment of Marketing Company with View to Developing Medical Robots
- Insurance Coverage for Rapid Detection of Colorectal Cancer and Stomach Cancer Lymph Node Metastasis Based on the OSNA® Method
- Sysmex Inostics and Bayer HealthCare collaborate to develop blood-based companion diagnostic tests for targeted tumor therapies
- Sysmex Selected for Inclusion in the Asia Pacific Index of the Dow Jones Sustainability Indexes for Second Consecutive Year
- Sysmex Acquiring Two Germany Based Companies to Expand its Technology Platform Targeting Personalized Medicine and Entering New Fields of Business
- Details of Stock Options (Stock Acquisition Rights) to be allocated (PDF：82KB)
- Concerning the Issuance of Stock Options (Stock Acquisition Rights) (PDF：61KB)
- Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2014 (PDF：152KB)
-
Sysmex Establishes R&D Center Americas in the United States
- Accelerating the Globalization of our R&D Structure with the Aim of Realizing Personalized Medicine - -
Sysmex Establishing New Instrument Factory to Meet Growing Global Demand
- Tripling Group Production Capacity by Simultaneously Expanding Sysmex and Affiliated Company Factories - - Sysmex Develops New Flag Technology for P. vivax and P. malariae
-
"Sysmex Forest" Established in Ono, Hyogo Prefecture
- Promoting Forest Conservation Activities Aimed at Making the Satoyama* a Place of Tranquility for People and Wildlife - - Consolidated Financial Results for the Year Ended March 31, 2013 (PDF：175KB)
- Notice Regarding Dividends from Surplus (PDF：16KB)
- Announcement of Executive Change (PDF：23KB)
-
Sysmex Announces New Group Mid-Term Management Plan
- Leveraging a Business Unit Structure to Accelerate Implementation Toward Achieving Long-Term Vision Objectives - -
Sysmex Strengthens Sales and Support in South Korea
- Transitioning to a Direct Sales and Support Organization with a View to Further Growth in Hematology and Non-Hematology Fields - - Announcement Regarding Revision of Business Forecasts (PDF：66KB)
- Sysmex Receives The Fiscal 2013 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology
- (Corrections and Corrections to Numerical Data)Partial Correction to Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2013 (PDF：81KB)
-
Sysmex to Be Special Sponsor of the Kobe Marathon 2013
- We are pleased to have sponsored this exciting event since its inception in 2011 - -
Announcement of Organizational and Personnel Changes
- Aiming to Accelerate Growth by Adopting a Structure Comprising Three Business Units - (PDF：109KB) - Sysmex Establishes Representative Office in Mongolia
- Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2013 *Revised on March 22, 2013 (PDF：183KB)
- XN-2000 and XN Reagents Win Germany’s iF Product Design Award 2013